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Abstract
Background: Dipeptidyl peptidase-3 (DPP3) is a metallopeptidase which cleaves bioactive peptides, notably
angiotensin II, and is involved in inflammation regulation. DPP3 has been proposed to be a myocardial depressant
factor and to be involved in circulatory failure in acute illnesses, possibly due to angiotensin II cleavage. In this
study, we evaluated the association between plasmatic DPP3 level and outcome (mortality and hemodynamic
failure) in severely ill burn patients.
Methods: In this biomarker analysis of a prospective cohort study, we included severely ill adult burn patients in
two tertiary burn intensive care units. DPP3 was measured at admission (DPP3admin) and 3 days after. The primary
endpoint was 90-day mortality. Secondary endpoints were hemodynamic failure and acute kidney injury (AKI).
Results: One hundred and eleven consecutive patients were enrolled. The median age was 48 (32.5–63) years, with
a median total body surface area burned of 35% (25–53.5) and Abbreviated Burn Severity Index (ABSI) of 8 (7–11).
Ninety-day mortality was 32%. The median DPP3admin was significantly higher in non-survivors versus survivors
(53.3 ng/mL [IQR 28.8–103.5] versus 27.1 ng/mL [IQR 19.4–38.9]; p < 0.0001). Patients with a sustained elevated DPP3
had an increased risk of death compared to patients with high DPP3admin but decreased levels on day 3. Patients
with circulatory failure had higher DPP3admin (39.2 ng/mL [IQR 25.9–76.1] versus 28.4 ng/mL [IQR 19.8–39.6]; p =
0.001) as well as patients with AKI (49.7 ng/mL [IQR 30.3–87.3] versus 27.6 ng/mL [IQR 19.4–41.4]; p = 0.001).
DPP3admin added prognostic value on top of ABSI (added chi
2 12.2, p = 0.0005), Sequential Organ Failure
Assessment (SOFA) score at admission (added chi2 4.9, p = 0.0268), and plasma lactate at admission (added chi2 6.9,
p = 0.0086) to predict circulatory failure within the first 48 h.
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Conclusions: Plasma DPP3 concentration at admission was associated with an increased risk of death, circulatory
failure, and AKI in severely burned patients. Whether DPP3 plasma levels could identify patients who would
respond to alternative hemodynamic support strategies, such as intravenous angiotensin II, should be explored.
Keywords: Dipeptidyl peptidase-3, Burn patients, Mortality, Acute kidney injury, Biomarkers
Background
Severe burn injury is associated with an early and pro-
found hypovolemia followed by an intense systemic in-
flammatory response. Hemodynamic management,
including fluid resuscitation, has long been recognized
as the cornerstone of the early management and
hemodynamic resuscitation of severely burned patients
[1–3]. However, a systemic inflammatory response may
be associated with distributive shock and/or acute myo-
cardial dysfunction [4]. Dipeptidyl peptidase-3 (DPP3),
also named enkephalinase B or red cell angiotensinase,
is a predominantly intracellular, ubiquitously expressed,
zinc-dependent metallopeptidase involved in the metab-
olism of peptides [5] implicated in many different path-
ways (e.g., blood pressure regulation, inflammation).
DPP3 cleaves bioactive peptides, notably angiotensin II,
enkephalins, and endomorphins [6–8]. We hypothesize
that cleavage of angiotensin II by DPP3 may promote
vasodilatation and circulatory failure. Severe burn pa-
tients are at high risk of developing vasodilatory shock
with systemic inflammatory response after the early
phase of hypovolemic shock. The main objective of this
study was therefore to assess the association between
DPP3 at admission (DPP3admin) and day 3 (DPP3Day3)
with 90-day mortality in severely burned patients. The
secondary objective was to evaluate the association be-
tween DPP3 and organ dysfunction (i.e., circulatory fail-
ure and acute kidney injury (AKI)).
Methods
Study design and population
We conducted a double-center cohort study in the Burn
Unit of Saint Louis Hospital (Assistance Publique Hôpi-
taux de Paris), Paris, and in the Burn Unit of Edouard
Herriot Hospital, Lyon, France. The study was approved
by our local ethic committee (PRONOBURN study,
comité de protection des personnes IV, St-Louis Hos-
pital; Institutional Review Board 00003835, protocol
2013/17NICB). All patients admitted to our intensive
care burn units (ICBU) between April 2014 and April
2016 and meeting the inclusion criteria were included.
Inclusion criteria were the following:
– A total body surface area [TBSA] burned > 15%
– Admission in the ICBU within the 72 h following
burn injury
– No decision to withdraw life support
– Available plasma sample at admission
Outcome
The endpoints were 90-day mortality, circulatory failure
in the first 48 h, and AKI.
Measurements
The following data have been collected: sex, age, body
mass index (BMI), TBSA, full-thickness body surface
area (BSA) burned, mechanism of injury and patients’
characteristics, Abbreviated Burn Severity Index (ABSI)
[9], Unit Burn Standard (UBS) [10], Sequential Organ
Failure Assessment (SOFA) score [11], 28- and 90-day
mortality, and AKI. Patients were resuscitated according
to the Intensive Care Burn Unit resuscitation protocol
[12]. A transthoracic or transesophageal echocardiog-
raphy was performed at admission of patients according
to the decision of the physician in charge. When per-
formed, left ventricular ejection fraction (LVEF) was
visually evaluated and systolic cardiac dysfunction was
defined by a LVEF < 50% [13]. Circulatory failure was
defined as a need for hemodynamic support with ino-
trope and/or a vasopressor (i.e., dobutamine, epineph-
rine, or norepinephrine) despite appropriate fluid
resuscitation in the first 48 h. We choose this time frame
to identify circulatory failure related to burn injury (as
opposed to sepsis or surgical procedures which occur
later during the course of burn injuries). AKI was de-
fined and staged according to the Kidney Disease: Im-
proving Global Outcomes (KDIGO) criteria [14] during
the first 7 days post admission. Admission serum cre-
atinine e (Screatadmin) was used as baseline Screat.
Venous blood samples were collected at admission and
at day 3 in tubes containing ethylene-diamine-tetra-acetic
acid. After centrifugation, plasma was kept frozen at −
80 °C until assayed. DPP3 was measured using the recently
developed DPP3 luminescence immunoassay [15].
Statistical analysis
Values are expressed as medians and interquartile ranges
(IQR) or counts and percentages as appropriate. Group
comparisons of continuous variables were performed
using Kruskal-Wallis test. Categorical data were com-
pared using Pearson’s chi-squared test for count data.
DPP3 data was log-transformed. Cox proportional-
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hazards regression was used to analyze the effect of risk
factors on survival in uni- and multivariable analyses,
and logistic regression was used for dichotomous end-
points. In both cases, to demonstrate independence from
other variables, the added value of DPP3 on top of these
was evaluated based on the likelihood ratio chi-squared
test for nested models. The concordance index (C index
or AUC) is given as an effect measure for uni- and mul-
tivariable models. For multivariable models, a bootstrap-
corrected version of the C index is given. For continuous
variables, hazard ratios (HR) or odds ratios (OR), as
appropriate, were standardized to describe the HR/OR
for a change of one IQR. HR (Cox regression) are used if
time-to-event data is available; OR (logistic regression)
are used if endpoints have event data (yes/no) only. Sur-
vival curves plotted by the Kaplan-Meier method were
used for illustrative purposes. For dichotomous end-
points, receiver operating characteristic (ROC) curves
were constructed for illustration. All statistical tests were
2-tailed and a two-sided p-value of 0.05 was considered
for significance. The statistical analyses were performed
using R version 3.4.3 (http://www.r-project.org, library
rms, Hmisc, ROCR) and Statistical Package for the
Social Sciences (SPSS) version 22.0 (SPSS Inc., Chicago,
Illinois, USA).
Results
Study population
From April 2014 to April 2016, 208 consecutive patients
met the inclusion criteria; 55 patients had missing
plasma at admission and were not included in the final
analysis, resulting in 111 patients that were analyzed.
The characteristics of the patients included in this study
are summarized in Table 1. The median age was 48
(32.5–63) years, with a median TBSA of 35% (25–53.5)
and median ABSI of 8 (7–11). All patients had a DPP3ad-
min measurement and 79 patients (71%) had DPP3Day3
(10 patients died before day 3 and 22 patients had miss-
ing measurements at day 3).
DPP3admin and 90-day mortality
Thirty-six (32%) patients died before day 90. Median
DPP3admin was significantly higher in non-survivors ver-
sus survivors (53.3 ng/mL [IQR 28.8–103.5] versus 27.1
ng/mL [IQR 19.4–38.9]; p < 0.0001). We observed a step-
wise increase in mortality among quartile groups of
DPP3admin, the patients in the highest quartile having
the highest mortality (Fig. 1). There was no interaction
between DPP3 value and TBSA (p = 0.7132) (Supple-
mentary Figure 1). The C index of DPP3admin for 90-day
mortality was 0.734 (0.653–0.815, p < 0.0001, standard-
ized HR 2.6 (1.9–3.6)). DPP3admin added prognostic
value on top of ABSI (added chi2 24.5, p < 0.0001), SOFA
score at admission (SOFAadmin, added chi
2 15.4, p <
0.0001), and lactate at admission (added chi2 11.7, p =
0.0006) to predict 90-day mortality (Fig. 2). Furthermore,
adding DPP3Day3 to DPP3admin provided added value to
predict 90-day mortality (added chi2 5.6, p = 0.018; miss-
ing data at day 3 replaced with admission data). Patients
with a high DPP3admin that decreased at day 3 had a bet-
ter prognosis than patients with high DPP3admin and sus-
tained DPP3Day3 (Fig. 3).
DPP3 and circulatory failure
Fifty-three (48%) patients had circulatory failure during
the first 48 h (44 patients received norepinephrine, five
patients received dobutamine + norepinephrine, 4
patients received epinephrine). DPP3admin was signifi-
cantly higher in patients with circulatory failure com-
pared to patients without (39.2 ng/mL [IQR 25.9–76.1]
versus 28.4 ng/mL [IQR 19.8–39.6]; p = 0.001) (Fig. 4 left
panel). DPP3admin was associated with circulatory failure
with an AUC of 0.680 (0.581–0.778, p < 0.0001, stan-
dardized OR 2.8 (1.6–4.9)). DPP3admin provided value on
top of ABSI (added chi2 12.2, p = 0.0005), SOFA score at
admission (SOFAadmin, added chi
2 4.9, p = 0.0268), and
lactate at admission (added chi2 6.9, p = 0.0086) to pre-
dict hemodynamic support in the first 48 h. There was
no correlation between DPP3 and the volume adminis-
tered on day 1 (r = 0.17, p = 0.07).
Fifty-nine patients (53%) had an echocardiography per-
formed at admission. Among them, 10 (17%) patients
had a systolic cardiac dysfunction. DPP3admin was signifi-
cantly higher in patients with systolic cardiac dysfunc-
tion compared to patients without (62.4 ng/mL [IQR
40.4–112.3] versus 29.3 ng/mL [IQR 22.4–45.1]; p <
0.0122) (Fig. 4 middle panel). The area under the ROC
curve for DPP3admin to predict systolic cardiac dysfunc-
tion was 0.753 (95%CI 0.582–0.925, p = 0.0054).
DPP3 and acute kidney injury
Thirty-five (32%) patients developed AKI during the first
7 days. DPP3admin was significantly higher in patients
with AKI compared to patients without (49.7 ng/mL
[IQR 30.3–87.3] versus 27.6 ng/mL [IQR 19.4–41.4]; p =
0.001) (Fig. 4 right panel). DPP3admin was associated with
AKI with an AUC of 0.735 (0.641–0.829, p = 0.0005,
standardized OR 2.3 (1.4–4.0)). DPP3admin added value
on top of ABSI (added chi2 9.4, p = 0.0022), SOFA score
at admission (SOFAadmin, added chi
2 14.3, p = 0.0002),
but not on top of creatinine at admission (added chi2
0.3, p = 0.5954) to predict AKI.
Discussion
In this biomarker analysis of a prospective cohort, we
observed that DPP3admin was strongly associated with
90-day mortality, circulatory failure, and AKI in severely
burned patients. Furthermore, adding DPP3admin to
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SOFAadmin, lactateadmin, or ABSI outperformed these
prognostic factors to predict 90-day mortality. Serial
measurements of DPP3 have improved the prediction of
outcome compared to DPP3admin alone.
While the prognosis of burn patients has improved, the
mortality of most severe patients remains high with many
patients dying from circulatory failure and multiple organ
failure [16, 17]. Initial hemodynamic management has
long been considered critical in the treatment and progno-
sis of burn patients [18]. Burn injury is characterized by
an initial hypodynamic state with low cardiac output due
to hypovolemia followed by a hyperdynamic state with
high cardiac output and low vascular resistance de-
veloping 12 to 24 h after the injury [1]. The severity
of the distributive shock and occurrence of cardiac
dysfunction may, however, vary greatly between
Table 1 Patients characteristics
Patient’s characteristics Total, N = 111 90-day survivors, N = 75 90-day non-survivors, N = 36 p
Sex, male—n (%) 71 (64) 51 (68) 20 (56) 0.2858
Age—year 48 [32.5–63] 42 [29–58] 56.5 [42–79] 0.0013
BMI—kg/m2 25.2 [22.9–28.7] 25.1 [23–28.3] 25.7 [22.4–29.1] 0.9673
Medical history
CIC—n (%) 3 (2.7) 2 (3) 1 (3) 1.0000
COPD—n (%) 3 (2.7) 2 (3) 1 (3) 1.0000
CKD—n (n) 5 (4.5) 1 (1) 4 (11) 0.0374
Chronic HBP—n (%) 25 (22.5) 12 (16) 13 (36) 0.0277
Psychiatric—n (%) 34 (30.6) 22 (29) 12 (33) 0.6668
Burn characteristics
TBSA—% 35 [25–53.5] 32 [22–45] 57 [31–70] < 0.0001
Deep burn BSA—% 21 [10–40] 17 [7–30] 42 [15–61] 0.0001
Inhalation injury—n (%) 54 (48.6) 28 (37) 26 (72) 0.0012
Characteristics during hospitalization
Mechanic ventilation—n (%) 82 (73.9) 52 (69) 30 (83) 0.1799
DPP3admin (ng/mL) 30.6 [22.4–53.6] 27.1 [19.4–40.2] 53.3 [29.5–104] < 0.0001
DPP3day3 (ng/mL) 17.3 [11.8–25.2] 14.1 [11.5–20.6] 22.1 [16.6–30.8] 0.0102
Screat—μmol/L 72.5 [56.5–92] 70 [54.8–81.3] 90.5 [67.3–138.3] 0.0003
Lactate—mmol/L 3.5 [2.0–5.7] 2.7 [1.7–4.6] 5.2 [3.5–8] < 0.0001
Bilirubin—mmol/L 14.0 [9.3–21.3] 12.9 [9–19.3] 18 [10.9–25.9] 0.0945
Platelet—G/L 250 [185–304] 236 [183–277] 279 [180–372] 0.3840
Length of hospitalization—days 90 [35.5–90] 41 [26–61] 18 [2–32.5] < 0.0001
RRT—n (%) 24 (21.6) 5 (7) 28 (78) < 0.0001
Severity scores
SOFA 4 [1–7] 2 [0–4] 6.5 [3.3–9.8] < 0.0001
ABSI 8 [7–11] 8 [6–9] 11 [9–13] < 0.0001
SAPS2 33 [23–47] 28 [20–42] 47 [33–62] < 0.0001
UBS 100 [52.5–166] 84 [45–132] 184 [86–249] < 0.0001
Hemodynamic on admission
Echocardiography, n (%) 59 (53) 33 (44) 26 (72) 0.0078
Systolic cardiac dysfunction, n (%) 10 (9) 2 (3) 8 (22) 0.0163
Circulatory failure, n (%) 53 (48) 24 (32) 29 (81) < 0.0001
MAP in mmHg 79 [70–95] 84 [73–97] 73 [64–85] 0.0104
Volume of crystalloids at day 1 8250 [3700–15,000] 6700 [3300–12,800] 13,400 [6430–18,380] 0.0018
Volume of crystalloids at day 2 3000 [1000–5650] 2500 [1000–5150] 4000 [2000–7500] 0.1078
BMI body mass index, CIC chronic ischemic cardiopathy, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, HBP high blood pressure, TBSA
total burn surface area, ECMO extracorporeal membrane oxygenation, Screat serum creatinine at admission, RRT renal replacement therapy, SOFA score simplified
organ failure assessment, ABSI Abbreviated Burn Severity Index, UBS Unit Burn Standard, SAPS 2 The Simplified Acute Physiology Score
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patients. The association between DPP3 levels, circula-
tory failure, and AKI is consistent with the current under-
standing of AKI in the critically ill, associating
hemodynamic factors and inflammation/immune re-
sponse [19, 20]. These results might also be expected in
patients developing systemic inflammatory response from
different causes (e.g., sepsis, post-cardiopulmonary bypass,
post-cardiac arrest, pancreatitis), and it should be further
explored.
In the current study, DPP3 was strongly associated
with mortality and hemodynamic failure, even after ad-
justment for classic markers of severity and prognosis.
Fig. 1 Represents a survival Kaplan-Meier curve depending on DPP3admin quartiles (legend gives quartile ranges for DPP3 in nanograms/milliliter)
Fig. 2 Represents unadjusted and adjusted (i.e., on Sequential Organ Failure Assessment-SOFA-OFA score or Abbreviated Burn Severity Index-
ABSI) hazard ratio (HR) and/or odds ratio (OR) of DPP3 admin value and outcomes (i.e., mortality, cardiac dysfunction, circulatory failure and acute
kidney injury, AKI, respectively). Mortality n = 111/36 events, HR not adjusted HR = 2.6 (1.9–3.6); adjusted on SOFA score, HR = 2.2 (1.5–3.2); and
adjusted on ABSI, HR = 2.6 (1.8–3.6), respectively. Circulatory failure, n = 111/53 events, OR not adjusted: OR = 2.8 (1.6–4.9); adjusted on SOFA score,
HR = 2.1 (1.0–4.2) and adjusted on ABSI, HR = 2.8 (1.4–5.4), respectively. Cardiac dysfunction, n = 59/10 events, OR not adjusted: OR = 2.8 (1.2–6.4);
adjusted on SOFA score, HR = 2.2 (0.96–5.0) and adjusted on ABSI, HR = 3.5 (1.3–9.2), respectively. Acute kidney injury (AKI) n = 111/35 events, OR
not adjusted: OR = 2.3 (1.4–4.0); adjusted on SOFA score, HR = 1.7 (0.93–3.0); and adjusted on ABSI, HR = 2.2 (1.3–3.7), respectively
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Recently, Deniau et al. observed an association between
high plasmatic levels of DPP3 and high mortality and
organ dysfunction in severe heart failure patients. Fur-
thermore, I.V. administration of DPP3 rapidly deterio-
rated cardiac contraction in mice [21]. In an ancillary
study of the OptimaCC study, Takagi et al. showed that
high circulating DPP3 was associated with low cardiac
index, refractory shock, and high mortality in patients
with cardiogenic shock [22].
The results of the present study have several poten-
tial implications for future research. First, the identifi-
cation of patients with high plasma DPP3 may trigger
cardiac function assessment. Second, high DPP3 levels
at admission may help to select candidate patients for
Fig. 3 Represents an illustration of the added value of DPP3day 3 using a cut point of 53.65 ng/mL at admission and day 3. Patients without DPP3
data at day 3 were left in their subgroup assigned to on day 1. High at admission and high at day 3 (HH): patients above 53.65 ng/mL at
admission and at day 3; high at admission and low at day 3 (HL): patients above 53.65 ng/mL at admission and below 53.65 ng/mL at day 3; low
at admission and high at day 3 low high (LH): patients below 53.65 ng/mL at admission and above 53.65 ng/mL at day 3; low at admission and
low at day 3 (LL): Patients below 53.65 ng/mL at admission and on day 3. Cut point identified is the third quartile (53.65 ng/mL)
Fig. 4 Represents median DPP3 admin between patients with and without circulatory failure in the first 48 h (left panel), between patients with or
without systolic cardiac dysfunction at admission (middle panel), and between patients with or without acute kidney injury (right panel)
Dépret et al. Critical Care          (2020) 24:168 Page 6 of 8
alternative vasopressor therapies, especially for infu-
sion of angiotensin II [23, 24]. Angiotensin II has
been found to be downregulated in some forms of
septic shock associated with poor prognosis [25].
DPP3 cleaves angiotensin II and may, therefore, play
a role in vasoplegic shock by reducing angiotensin II
levels. Since angiotensin II is not easy to measure in
clinical practice, DPP3 may represent a potential can-
didate biomarker for selecting patients most likely to
respond to angiotensin II infusion. Third, pharmaco-
logical inhibition of DPP3 by a specific antibody has
been shown to promptly restore and sustain cardiac
contraction in mice [21] and might be a therapeutic
option in burn patients with high DPP3. All these
strategies are hypothesis and require exploration and
validation in well-designed prospective human studies.
Our study has several limitations. First, the observa-
tional design of the present study does not allow us to
conclude on the causality between DPP3 and mortality
or organ dysfunction. Second, the study contains a rela-
tively low number of patients, even though this is one of
the largest cohort studies among critically ill burn
patients with sufficient power to identify an association
between the biomarker levels and outcomes. Thirdly,
factors influencing DPP3 metabolism are unknown and
will need further exploration in critically ill burn
patients. Finally, only half of our patients had an echo-
cardiography at admission, limiting the interpretation of
the association between DPP3 levels and cardiac
dysfunction.
Conclusion
Plasma DPP3 concentration at admission was associated
with an increased risk of death, circulatory failure, and
AKI in severely burned patients. Whether DPP3 plasma
levels could identify patients who would respond to al-
ternative hemodynamic support strategies, such as intra-
venous angiotensin II, should be explored.
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